Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia

Completed · Phase 2

Conditions studied: Parkinson's Disease, Dyskinesia

In brief

The primary purpose of the study is to investigate the anti-dyskinetic effect of several doses of sarizotan in Parkinson patients in order to generate information on the dose-response relationship (dose-finding).

Key facts

Study ID

NCT00314288

Run by

EMD Serono

People needed

360

Starts

2002-07-01

Expected to finish

2003-07-01

Last updated by the study team

2017-01-23

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or Female
• The subject is an out-patient
• Age 30 years or above
• Dyskinesias present during more than 25% of the waking day
• Dyskinesias at least moderately disabling
• Written informed consent

You may not qualify if…

• Pregnancy and/or lactation
• Participation in another study within the last 30 days
• Dementia or other psychiatric illness that prevents provision of informed consent
• History of allergic disorders such as asthma
• Known hypersensitivity to the study treatment(s)
• Known hypersensitivity to ACTH

Where it is running

• Study site — Sunnyvale, California, United States
• Study site — Miami, Florida, United States
• Study site — Tampa, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Chicago, Illinois, United States
• Study site — Augusta, Maine, United States
• Study site — Boston, Massachusetts, United States
• Study site — Kansas City, Missouri, United States
• Study site — Brooklyn, New York, United States
• Study site — New York, New York, United States
• Study site — Cincinnati, Ohio, United States
• Study site — Columbus, Ohio, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Pawtucket, Rhode Island, United States
• Study site — Memphis, Tennessee, United States
• Study site — Houston, Texas, United States
• Study site — Leuven, Belgium
• Study site — Sofia, Bulgaria
• Study site — Edmonton, Canada
• Study site — Saskatoon, Canada
• Study site — Vancouver, Canada
• Study site — Clermont-Ferrand, France
• Study site — Marseille, France
• Study site — Nantes, France
• Study site — Fountain Valley, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.